Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma

 Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma  LAVAL, Quebec, July 10, 2014 /CNW/ - Valeant Pharmaceuticals International,  Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to  Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport  owned or held by Valeant for $1.4 billion in cash, pursuant to the previously  announced agreement with Nestle S.A, which recently completed its acquisition  of Galderma.  "We are pleased to complete the divestiture of our products to a company that  is firmly committed to the aesthetic dermatology market," said J. Michael  Pearson, chairman and chief executive officer.  "Humberto Antunes, CEO of  Galderma, has embraced our commercial team and I know he will continue our  efforts to build strong relationships with the healthcare leaders in this  industry."  About Valeant Pharmaceuticals International, Inc.  Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational  specialty pharmaceutical company that develops, manufactures and markets a  broad range of pharmaceutical products primarily in the areas of dermatology,  eye health, neurology and branded generics.  More information about Valeant  Pharmaceuticals International, Inc. can be found at www.valeant.com.  Contact Information:  Laurie W. Little 949-461-6002  laurie.little@valeant.com  Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO    SOURCE  Valeant Pharmaceuticals International, Inc.  http://www.valeant.com  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO  To view this news release in HTML formatting, please use the following URL:  http://www.newswire.ca/en/releases/archive/July2014/10/c7349.html  CO: Valeant Pharmaceuticals International, Inc. ST: Quebec NI: HEA MTC BTC MNA  
Press spacebar to pause and continue. Press esc to stop.